Diosmin + Hesperidin: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Acute haemorrhoidal attack

Adult: Available preparations:
Each 500 mg tab contains MPFF corresponding to diosmin 450 mg and hesperidin 50 mg
Each 1,000 mg tab contains MPFF corresponding to diosmin 900 mg and hesperidin 100 mg

Recommended dose: 1,000 mg tid for the 1st 4 days, followed by 1,000 mg bid for the next 3 days. Seek medical advice if symptoms do not resolve within 15 days.

Oral
Chronic venous insufficiency

Adult: Available preparations:
Each 500 mg tab contains micronised purified flavonoid fraction (MPFF) corresponding to diosmin 450 mg and hesperidin 50 mg
Each 1,000 mg tab contains MPFF corresponding to diosmin 900 mg and hesperidin 100 mg

For cases of the lower limbs (e.g. heavy legs, early morning restless leg, pain): Recommended dose: 500 mg bid or 1,000 mg once daily.

Oral
Chronic haemorrhoids

Special Precautions

Pregnancy and lactation.

Adverse Reactions

Gastrointestinal disorders: Diarrhoea, dyspepsia, nausea, vomiting, colitis, abdominal pain, constipation.
Immune system disorders: Angioedema.
Metabolism and nutrition disorders: Isolated oedema.
Nervous system disorders: Rarely, headache, dizziness.
Skin and subcutaneous tissue disorders: Rarely, rash, pruritus, urticaria.

Drug Interactions

May increase the serum concentrations of substrates of CYP2E1 (e.g. chlorzoxazone), CYP2C9 (e.g. diclofenac Na), or P-glycoprotein (e.g. fexofenadine).

Action

Description: Diosmin and hesperidin are venotonic and vasoprotective flavonoid compounds. The combination reduces venous distensibility and stasis, and normalises capillary permeability and reinforces capillary resistance in the microcirculation.
Diosmin is synthesised from hesperidin. It acts as a phlebotonic and vascular protector for venous leg ulcers and haemorrhoids.
Synonym: diosmin: diosmine.
Pharmacokinetics:
Absorption: Diosmin: Time to peak plasma concentration: 1 hour.
Distribution: Diosmin: Volume of distribution: 54.2-70 L.
Metabolism: Diosmin: Rapidly hydrolysed in the intestine by the gut microbiome into the active metabolite, diosmetin.
Excretion: Diosmin: Via faeces (approx 50% as unchanged drug or metabolite); urine (approx 14%). Elimination half-life: 11 hours.

Chemical Structure

Storage

Store below 30°C.

MIMS Class

Phlebitis & Varicose Preparations

ATC Classification

C05CA53 - diosmin, combinations ; Belongs to the class of bioflavonoids used as capillary stabilizing agents.

References

Anon. Diosmin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/10/2020.

Ardium 1000 (Servier). MIMS Indonesia. http://www.mims.com/indonesia. Accessed 20/10/2020.

Aveflon 500 mg Tablet (Xepa-Soul Pattinson [Malaysia] Sdn Bhd). MIMS Malaysia. http://www.mims.com/malaysia. Accessed 07/10/2020.

Buckingham R (ed). Flavonoid Compounds. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/10/2020.

Daflon 1000 mg Film-Coated Tablet (Servier Philippines, Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 07/10/2020.

Daflon 500 mg Film-Coated Tablet (Servier Malaysia Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my/. Accessed 07/10/2020.

Hespadin 500 mg Film-Coated Tablet (SRS Pharmaceuticals Phils. Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 20/10/2020.

Disclaimer: This information is independently developed by MIMS based on Diosmin + Hesperidin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com